Filtered By:
Source: European Heart Journal
Condition: Heart Disease

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes
Conclusion Differences in baseline characteristics in patients with increasing severities of PVR may increase the risk of this complication. Despite these differences, multivariable analysis demonstrated that both mild and moderate/severe PVR predicted higher 1-year mortality.
Source: European Heart Journal - February 14, 2015 Category: Cardiology Authors: Kodali, S., Pibarot, P., Douglas, P. S., Williams, M., Xu, K., Thourani, V., Rihal, C. S., Zajarias, A., Doshi, D., Davidson, M., Tuzcu, E. M., Stewart, W., Weissman, N. J., Svensson, L., Greason, K., Maniar, H., Mack, M., Anwaruddin, S., Leon, M. B., Hah Tags: Valvular heart disease Source Type: research

Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study
Conclusion For type 2 diabetes, the MHO phenotype is associated with lower risk than the metabolically unhealthy obese, but for CVD the risk is as elevated in both obesity phenotypes.
Source: European Heart Journal - March 1, 2015 Category: Cardiology Authors: Hinnouho, G.-M., Czernichow, S., Dugravot, A., Nabi, H., Brunner, E. J., Kivimaki, M., Singh-Manoux, A. Tags: Prevention and epidemiology Source Type: research

Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)
Conclusion Rheumatic heart disease patients were young, predominantly female, and had high prevalence of major cardiovascular complications. There is suboptimal utilization of secondary antibiotic prophylaxis, oral anti-coagulation, and contraception, and variations in the use of percutaneous and surgical interventions by country income level.
Source: European Heart Journal - May 7, 2015 Category: Cardiology Authors: Zuhlke, L., Engel, M. E., Karthikeyan, G., Rangarajan, S., Mackie, P., Cupido, B., Mauff, K., Islam, S., Joachim, A., Daniels, R., Francis, V., Ogendo, S., Gitura, B., Mondo, C., Okello, E., Lwabi, P., Al-Kebsi, M. M., Hugo-Hamman, C., Sheta, S. S., Haile Tags: Valvular heart disease Source Type: research

Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data
Conclusion The fusion AVAi reclassifies 52% of normal flow–low gradient and 12% of low flow–low gradient severe AS into true moderate AS, by providing true cross-sectional LVOT area.
Source: European Heart Journal - August 14, 2015 Category: Cardiology Authors: Kamperidis, V., van Rosendael, P. J., Katsanos, S., van der Kley, F., Regeer, M., Al Amri, I., Sianos, G., Marsan, N. A., Delgado, V., Bax, J. J. Tags: Valvular heart disease Source Type: research

Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts
Conclusion In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice.
Source: European Heart Journal - December 21, 2015 Category: Cardiology Authors: Olson, K. A., Beatty, A. L., Heidecker, B., Regan, M. C., Brody, E. N., Foreman, T., Kato, S., Mehler, R. E., Singer, B. S., Hveem, K., Dalen, H., Sterling, D. G., Lawn, R. M., Schiller, N. B., Williams, S. A., Whooley, M. A., Ganz, P. Tags: Pathophysiology Source Type: research

Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction vs. speckle tracking global longitudinal strain
Conclusion In patients with severe secondary MR, speckle-tracking GLS shows more deteriorated LV systolic function than LVEF.
Source: European Heart Journal - March 7, 2016 Category: Cardiology Authors: Kamperidis, V., Marsan, N. A., Delgado, V., Bax, J. J. Tags: Valvular heart disease Source Type: research

Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease
Conclusion Greater consumption of healthy foods may be more important for secondary prevention of coronary artery disease than avoidance of less healthy foods typical of Western diets.
Source: European Heart Journal - June 30, 2016 Category: Cardiology Authors: Stewart, R. A. H., Wallentin, L., Benatar, J., Danchin, N., Hagstrom, E., Held, C., Husted, S., Lonn, E., Stebbins, A., Chiswell, K., Vedin, O., Watson, D., White, H. D., the STABILITY Investigators Tags: Coronary artery disease Source Type: research

Prediction of adverse events after catheter-based procedures in adolescents and adults with congenital heart disease in the IMPACT registry
ConclusionThe factors predicting adverse events after cardiac catheterization in adolescents and adults with CHD are different than in the general population. Validation of this model in other national or multi-institutional datasets is the next step.
Source: European Heart Journal - April 18, 2017 Category: Cardiology Source Type: research

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
AbstractIn 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace 2013;15:625 –651; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in...
Source: European Heart Journal - June 9, 2016 Category: Cardiology Source Type: research

Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial
ConclusionIn patients with stable coronary heart disease, higher visit-to-visit variabilities of both systolic and diastolic BP are strong predictors of increased risk of cardiovascular events, independently of mean BP.
Source: European Heart Journal - May 27, 2017 Category: Cardiology Source Type: research

An African cardiology summitThe World Heart Federation African Summit on Best Practices in Policy and Access to Care in 2017 concluded with the Khartoum Action Plan, to improve cardiovascular on the African continent
The World Heart Federation (WHF) is the umbrella organization of continental and national cardiac societies and heart foundations globally, reporting to the World Health Organization (WHO). The WHF is dedicated to the global fight against CVD, including heart disease, stroke, and rheumatic heart disease (RHD). Building on the first Global Summit on Circulatory Health, held at the 2016 World Congress of Cardiology and Cardiovascular Health in Mexico City, the second Summit held in Singapore July 2017 focused on building a civil society movement for circulatory health.
Source: European Heart Journal - February 6, 2018 Category: Cardiology Source Type: research

Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update
AbstractSubclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo), defined as elevated thyroid-stimulating hormone (TSH) by normal free thyroxine (FT4), and subclinical hyperthyroidism (SHyper) with decreased or undetectable TSH and normal FT4. Up to 10% of the elderly have SHypo, which is usually asymptomatic. Individual participant data (IPD) analyses of prospective cohort studies from the international Thyroid Studies Collaboration show that SHypo is associated with increased coronary heart disease (CHD) mortality [hazard ratio (HR) 1,58 for TSH ≥ 10 mIU/L, 95% CI 1.10–2.27), as well as increased ...
Source: European Heart Journal - February 27, 2017 Category: Cardiology Source Type: research

Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)
ConclusionsCoronary artery calcium is associated strongly and in a graded fashion with 10-year risk of incident ASCVD as it is for CHD, independent of standard risk factors, and similarly by age, gender, and ethnicity. While 10-year event rates in those with CAC  = 0 were almost exclusively below 5%, those with CAC ≥ 100 were consistently above 7.5%, making these potentially valuable cutpoints for the consideration of preventive therapies. Coronary artery calcium strongly predicts risk with the same magnitude of effect in all races, age groups, an d both sexes, which makes it among the most useful markers for predicting ASCVD risk.
Source: European Heart Journal - April 23, 2018 Category: Cardiology Source Type: research

Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index
ConclusionAmong postmenopausal women with normal BMI, both elevated trunk fat and reduced leg fat are associated with increased risk of CVD.
Source: European Heart Journal - June 30, 2019 Category: Cardiology Source Type: research

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
ConclusionsIn patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR  >  60 mL/min/1.73 m2.
Source: European Heart Journal - August 21, 2020 Category: Cardiology Source Type: research